P-scores for ranking the treatments were as follows: FGF21 (0.93), Resmetirom (0.61), and GLP-1 (0.46), indicating that FGF21 agonists had the highest probability of being the most effective treatment for NASH resolution. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.